GRUSF
Grown Rogue International Inc.
$0.4800
+11.63%
No data for this timeframe.
Vol
SEC Reports4
Recent Activity
May 1, 2026
SEC
Grown Rogue International filed an Amendment No. 1 to its 2025 Form 10-K solely to correct a typographical error on the
10-K/A — Impact 2/10
Apr 27, 2026
SEC
Grown Rogue International Inc. announced it will report its first quarter 2026 financial results after market close on M
8-K — Impact 2/10
Apr 7, 2026
SEC
Grown Rogue reported preliminary 2025 full-year revenue of $32.4M (22% YoY growth) and Adjusted EBITDA of $5.4M (42% gro
8-K — Impact 6/10
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Latest Reports
NEUTRAL
10-K/A
2/10
Grown Rogue International filed an Amendment No. 1 to its 2025 Form 10-K solely to correct a typographical error on the
May 1, 2026
NEUTRAL
8-K
2/10
Grown Rogue International Inc. announced it will report its first quarter 2026 financial results after market close on M
Apr 27, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 3.5/10.
NEUTRAL
10-K/A
2/10
Grown Rogue International filed an Amendment No. 1 to its 2025 Form 10-K solely to correct a typogra
May 1, 2026
NEUTRAL
8-K
2/10
Grown Rogue International Inc. announced it will report its first quarter 2026 financial results aft
Apr 27, 2026
BULLISH
8-K
6/10
Grown Rogue reported preliminary 2025 full-year revenue of $32.4M (22% YoY growth) and Adjusted EBIT
Apr 7, 2026
NEUTRAL
8-K
4/10
Analysis based on filing metadata only — document content was unavailable. The 8-K filing for Grown
Mar 18, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY 2027-10-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Mar 1, 2022 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2022 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2022 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Dec 1, 2021 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.